Latest news with #bispecificantibody
Globe and Mail
20-05-2025
- Business
- Globe and Mail
Pfizer Buys Rights to PD-1 & VEGF Inhibitor From China Biotech
Pfizer PFE announced that it is in-licensing global development and commercialization rights, ex-China, to SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, from Chinese biotech, 3SBio. 3SBio is already developing SSGJ-707 in China for non-small cell lung cancer ('NSCLC'), metastatic colorectal cancer, and gynecological tumors, with the first phase III study expected to begin this year. Unlike the currently available marketed products, which target only the PD-1 protein, SSGJ-707 targets two proteins, PD-1 and VEGF. The blockade of two proteins, PD-1 and VEGF, can lead to a more robust anti-tumor response, compared to targeting either pathway alone For the deal, Pfizer will make an upfront payment of $1.25 billion to 3SBio, with the latter also being entitled to milestone payments of up to $4.8 billion as well as tiered double-digit royalties on sales of SSGJ-707, if approved. Pfizer will also make an equity investment of $100 million in 3SBio upon close, subject to an agreement. Pfizer also retains an option for rights to commercialization in China. The transaction is expected to be closed in the third quarter. Pfizer's stock has declined 10.2% so far this year compared with a decrease of 4.0% for the industry. SMMT's Dual PD-1/VEGF Inhibitor Summit Therapeutics SMMT is also developing a dual PD-1 and VEGF inhibitor, ivonescimab, in collaboration with China-based Akeso. The company acquired an exclusive license from Akeso in 2022 to develop and market the drug in the United States, Canada, Europe and Japan. Ivonescimab is already approved only in China to treat EGFR-mutated, locally advanced or metastatic non-squamous NSCLC. In 2024, Summit Therapeutics reported positive data from a phase III study (conducted in China by partner Akeso) in patients with locally advanced or metastatic NSCLC, in which ivonescimab, outperformed Merck 's MRK blockbuster PD-L1 inhibitor, Keytruda. Summit believes ivonescimab has the potential to replace Merck's Keytruda as the next standard of care across multiple NSCLC settings. PFE's Zacks Rank Pfizer currently has a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2024. While not all picks can be winners, previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. Today, See These 5 Potential Home Runs >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report Summit Therapeutics PLC (SMMT): Free Stock Analysis Report
Yahoo
20-05-2025
- Business
- Yahoo
Pfizer signs global licensing deal with 3SBio for bispecific antibody
Pfizer has signed a worldwide licensing agreement, excluding China, with biopharmaceutical company 3SBio to develop, manufacture and commercialise bispecific antibody targeting programmed cell death protein 1 (PD-1) and vascular endothelial growth factor (VEGF), SSGJ-707. 3SBio, along with its subsidiaries Shenyang Sunshine Pharmaceutical and 3S Guojian Pharmaceutical (Shanghai), will grant Pfizer exclusive global rights to SSGJ-707 outside of China. Pfizer retains the option for commercialisation rights within China. Pfizer will pay 3SBio $1.25bn upfront could earn up to $4.8bn in milestone payments, subject to the achievement of specific development, regulatory and commercial targets. 3SBio is also set to receive tiered double-digit royalties on future sales of SSGJ-707, contingent upon regulatory approval. The transaction will be finalised in the third quarter of 2025, pending customary closing conditions, including necessary regulatory approvals and the endorsement of 3SBio shareholders. Pfizer will invest $100m in 3SBio under a securities subscription agreement between the two entities. Pfizer plans to produce the drug substance for the antibody in the US state of North Carolina and the drug product in McPherson, Kansas. SSGJ-707 is currently undergoing trials in China for non-small cell lung cancer, gynaecological tumours and metastatic colorectal cancer. 3SBio is preparing to initiate the first Phase III trial in the country in 2025. Following the announcement of this agreement, 3SBio's shares saw a significant increase of 35% in Hong Kong's market, bringing the company's valuation to $6bn, as reported by Reuters. In March 2025, Pfizer completed the divestiture of its remaining stake in Haleon, amounting to 7.3% of the issued share capital, for £2.55bn ($3.3bn). This marked the end of a multi-year separation from GSK's former Consumer Healthcare business, which now operates independently as Haleon. "Pfizer signs global licensing deal with 3SBio for bispecific antibody" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
